US · PHR
Phreesia, Inc.
- Sector
- Healthcare · Medical - Healthcare Information Services
- Headquarters
- Wilmington, NC 27601
- Website
- phreesia.com
Price · as of 2025-01-31
$9.67
Market cap 743.34M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $65.00 | +572.18% |
| Intrinsic Value(DCF) | $28.53 | +195.04% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | |||||
| 2019 | $0.00 | $0.00 | |||
| 2020 | $19.75 | $101.00 | $123.96 | $0.00 | $0.00 |
| 2021 | $52.88 | $49.69 | $38.61 | $3.00 | $0.00 |
| 2022 | $27.77 | $799.79 | $146.49 | $0.00 | $0.00 |
| 2023 | $30.49 | $32.36 | $160.44 | $0.00 | $0.00 |
| 2024 | $23.58 | $36.27 | $200.52 | $0.00 | $0.00 |
| 2025 | $24.06 | $65.00 | $87.22 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Phreesia, Inc.'s (PHR) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $65.00
- Current price
- $9.67
- AI upside
- +572.18%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$28.53
+195.04% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| PHR | Phreesia, Inc. | $9.67 | 743.34M | +572% | +195% | — | — | -23.67 | 5.23 | 3.30 | -51.58 | — | 12.82 | 67.86% | -13.84% | -13.94% | -22.67% | -31.04% | -15.43% | 0.07 | -24.75 | 1.78 | 1.38 | 2.60 | -5936.00% | 1783.00% | -11443.00% | 0.60% | 0.28 | 4.43% | 0.00% | 0.00% | 0.00% | -22.71 | 159.09 | 3.14 | 4.70 |
| BLFS | BioLife Solutions, Inc. | $24.20 | 1.17B | +49% | -55% | -73% | — | — | 2.89 | 11.18 | -103.07 | — | 2.89 | 64.56% | -12.61% | -12.61% | 0.00% | -4.52% | 0.00% | 0.03 | -4.48 | 5.23 | 5.23 | -1.18 | -4318.00% | 1697.00% | 28653.00% | 1.87% | 0.88 | 7.49% | 0.00% | — | 0.00% | -79.66 | 48.04 | 10.04 | 18.23 |
| ESTA | Establishment Labs Holdin… | $78.70 | 2.29B | -26% | +32% | — | — | -44.15 | 95.73 | 10.68 | -66.58 | — | 181.85 | 69.32% | -18.48% | -24.19% | -133.25% | -49.45% | -14.51% | 0.12 | -1.54 | 3.04 | 1.86 | 2.22 | -4267.00% | 2714.00% | -2314.00% | -2.53% | -0.62 | -82.02% | 0.00% | 0.00% | 9.21% | -55.92 | -38.31 | 10.34 | 4.85 |
| GDRX | GoodRx Holdings, Inc. | $1.87 | 635.85M | +1,396% | -39% | -10% | +8% | 30.91 | 1.25 | 0.97 | 3.10 | 29.70 | 6.35 | 92.77% | 10.98% | 10.37% | 3.73% | 14.18% | 1.79% | 0.10 | 2.05 | 2.61 | 2.02 | -1.10 | 10407.00% | 57.00% | -3234.00% | 9.94% | 0.55 | 12.45% | 0.00% | 0.00% | 65.21% | 6.53 | 7.43 | 0.72 | 0.29 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $23.28 | 1.36B | +67% | +283% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| NEOG | Neogen Corporation | $11.23 | 2.44B | +204% | -82% | — | — | -1.01 | 0.53 | 1.23 | -2.01 | -0.01 | -2.73 | 47.10% | 1.05% | -122.06% | -41.88% | 0.27% | -27.33% | 0.44 | 0.13 | 3.32 | 1.62 | -0.84 | 1146322.00% | -320.00% | -3914.00% | -4.21% | 0.33 | -1.38% | 0.00% | 0.00% | 0.00% | 200.15 | -40.68 | 2.11 | 0.67 |
| NVCR | NovoCure Limited | $13.67 | 1.53B | +107% | -55% | — | — | -11.06 | 4.43 | 2.30 | -11.25 | — | 4.43 | 74.54% | -23.47% | -20.79% | -38.89% | -119.85% | -13.32% | 0.85 | — | 2.90 | 2.57 | -1.57 | -2179.00% | 828.00% | 932.00% | -5.02% | -0.22 | -58.98% | 0.00% | 0.00% | 22.09% | -8.71 | -17.70 | 2.04 | 0.52 |
| OMCL | Omnicell, Inc. | $41.10 | 1.89B | +33% | -57% | -73% | -98% | 924.00 | 1.54 | 1.60 | 19.91 | — | 5.86 | 42.49% | 0.44% | 0.17% | 0.17% | 0.17% | 0.10% | 0.18 | 0.84 | 1.43 | 0.87 | 0.21 | -8359.00% | 653.00% | -4256.00% | 4.58% | 0.27 | 6.96% | 0.00% | 0.00% | 4.09% | 371.46 | 22.06 | 1.62 | 2.26 |
| OMDA | Omada Health | $12.28 | 711.11M | — | — | — | — | — | — | — | — | — | — | 60.59% | -25.71% | -27.76% | -57.64% | -270.44% | -28.92% | 0.47 | -9.69 | 2.10 | 1.86 | 1.22 | -2975.00% | 3829.00% | -2776.00% | — | -0.63 | -235.67% | — | 0.00% | — | — | — | — | — |
| SDGR | Schrödinger, Inc. | $12.06 | 888.4M | +184% | -53% | — | — | -8.64 | 2.45 | 3.49 | -6.29 | — | 2.48 | 55.74% | -65.23% | -40.36% | -26.29% | -125.97% | -13.33% | 0.30 | — | 2.75 | 2.53 | 1.26 | -4514.00% | 2329.00% | -10756.00% | 1.40% | 0.07 | 9.40% | 0.00% | 0.00% | 10.29% | -3.63 | 48.66 | 2.37 | 0.41 |
| TDOC | Teladoc Health, Inc. | $5.26 | 933.51M | +398% | -42% | -89% | — | -4.54 | 0.66 | 0.36 | 7.86 | — | -4.67 | 69.50% | -10.39% | -7.92% | -13.93% | -13.11% | -6.28% | 0.74 | -13.34 | 2.77 | 2.41 | 1.68 | -8058.00% | -154.00% | 91.00% | 31.39% | 0.73 | 16.74% | 0.00% | 0.00% | 4.21% | -4.40 | 4.05 | 0.46 | -6.80 |
About Phreesia, Inc.
Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for processing of patient payments. The company deploys its platform in a range of modalities, such as Phreesia Mobile, a patients' mobile device; Phreesia Dashboard, a web-based dashboard for healthcare services clients; PhreesiaPads, which are self-service intake tablets; and Arrivals Kiosks that are on-site kiosks. Its Phreesia Platform also provides a registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, and cost estimation tools; access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking; and life sciences solution to deliver targeted and clinically relevant marketing content to patients. In addition, the company's Phreesia Platform offers clinical support solution, which collects clinical intake and patient reported outcome (PRO) data for approximately 25 specialties, as well as enables healthcare services clients to communicate with their patients through surveys, announcements, text and email messaging, and health campaigns; and COVID-19 support modules for managing COVID-19 vaccine delivery and identify vaccine-hesitant patients, screening for self-reported COVID-19 risk factors, enabling contactless check-in during in-person visits, and collecting intake information during telehealth visits. It serves patients; single-specialty practices, multi-specialty groups, and health systems; and pharmaceutical, medical device, and biotechnology companies. The company was incorporated in 2005 and is headquartered in Raleigh, North Carolina.
- CEO
- Chaim Indig
- Employees
- 2.08K
- Beta
- 0.66
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($28.53 ÷ $9.67) − 1 = +195.04% (DCF, example).